Cellbion: Files for Phase 3 trial of Lutetium (177Lu) DGUL for metastatic castration-resistant prostate cancer

FDA clears Phase 3 trial for prostate cancer drug Lutetium (177Lu) DGUL

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).